Clinical trial
Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage…
NCT00216125 · Nasser Hanna, M.D., Other · Completed
Key facts
| NCT number | NCT00216125 |
|---|---|
| Title | Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer |
| Official title | A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With or Without Consolidation Docetaxel in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN01-24 |
| Lead sponsor | Nasser Hanna, M.D., Other |
| Collaborators | Sanofi Industry Walther Cancer Institute |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug, Radiation |
| Interventions | Cisplatin, Etoposide, Radiation, Docetaxel |
| Enrollment | 243 |
| Start date | Feb 1, 2002 |
| Primary completion | Jun 1, 2006 |
| Completion | Mar 1, 2008 |
| First posted | Sep 22, 2005 |
| Last update posted | Mar 16, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: